Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion
Patrick Dolezal

Patrick Dolezal Analyst Performance

Managing Director, Senior Research Analyst at Lifesci Capital

Patrick Dolezal is a stock analyst at Lifesci Capital in the medical sector, covering 3 publicly traded companies. Over the past year, Patrick Dolezal has issued 2 stock ratings, including and buy recommendations. While full access to Patrick Dolezal's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Patrick Dolezal's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 4 Years
Buy Recommendations
66.67% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%2 ratings
Hold33.3%1 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Patrick Dolezal at Lifesci Capital, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Patrick Dolezal, an analyst at Lifesci Capital, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Patrick Dolezal of Lifesci Capital specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
MED - DRUGS
1 company
33.3%

About Patrick Dolezal

Patrick Dolezal is a Senior Research Analyst with LifeSci Capital, having recently re-joined the firm after spending 2 years co-founding Mantle Therapeutics. At Mantle, Patrick held various roles including Co-CEO, CFO, and COO. Patrick previously spent >8 years at LifeSci primarily as a Senior Research Analyst, covering diverse therapeutic areas that included metabolic disorders, rare diseases, and ophthalmology. Patrick began his career with the firm as a Research Associate in 2015, before being promoted to Research Analyst in 2016. He undertook graduate studies at New York University, completing his thesis in a translational neurology lab at Langone focused on amyloid-beta vaccination strategies for Alzheimer’s disease. Patrick earned his BS in Biology at Indiana University.
Follow on LinkedIn

Patrick Dolezal's Ratings History at Lifesci Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Neurogene Inc. stock logo
NGNE
Neurogene
1/26/2026Initiated Coverage$18.31$50.00Outperform
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
10/23/2025Initiated Coverage$17.11$40.00Outperform